Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11

Guggenheim analyst Vamil Divan has initiated coverage on Entera Bio (NASDAQ: ENTX) with a Buy rating. The firm has set a price target of $11 for the company's stock.